KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Payables (2016 - 2025)

Neogenomics' Payables history spans 16 years, with the latest figure at $23.1 million for Q4 2025.

  • For Q4 2025, Payables fell 89.62% year-over-year to $23.1 million; the TTM value through Dec 2025 reached $23.1 million, down 89.62%, while the annual FY2025 figure was $23.1 million, 89.62% down from the prior year.
  • Payables reached $23.1 million in Q4 2025 per NEO's latest filing, up from $22.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $222.4 million in Q4 2024 to a low of $13.7 million in Q3 2022.
  • Average Payables over 5 years is $60.2 million, with a median of $21.6 million recorded in 2022.
  • Peak YoY movement for Payables: soared 1189.84% in 2024, then tumbled 89.62% in 2025.
  • A 5-year view of Payables shows it stood at $17.9 million in 2021, then grew by 14.45% to $20.5 million in 2022, then dropped by 0.86% to $20.3 million in 2023, then soared by 993.66% to $222.4 million in 2024, then crashed by 89.62% to $23.1 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Payables are $23.1 million (Q4 2025), $22.6 million (Q3 2025), and $27.5 million (Q2 2025).